Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ: BMRN )

68.99 -1.61 (-2.28%)
Streaming Delayed Price Updated: 9:41 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
1 Healthcare Stock to Target This Week and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
BIOMARIN PHARMACEUTICAL INC has a stellar value proposition. NASDAQ:BMRN not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Demystifying Biomarin Pharmaceutical: Insights From 8 Analyst Reviews
Via Benzinga
Earnings Scheduled For February 19, 2025
Via Benzinga
NASDAQ:BMRN, a growth stock which is not overvalued.
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. 
Via Chartmill
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know. 
Via StockStory
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know. 
Via StockStory
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know. 
Via StockStory
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today
Via The Motley Fool
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company reported impressive fourth-quarter results, exceeding analysts' sales and EPS... 
Via StockStory
The Latest Analyst Ratings For Biomarin Pharmaceutical
Via Benzinga
Why Is BioMarin Stock Trading Higher On Thursday?
BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results. 
Via Benzinga
BioMarin: EPS Surges Past Expectations
BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. 
Via The Motley Fool
BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 15.6% year on year to $747.3 million. The company’s full-year... 
Via StockStory
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target. 
Via Benzinga
The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
NASDAQ:BMRN is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
NASDAQ:BMRN is an undervalued gem with solid fundamentals.
Take a closer look at BIOMARIN PHARMACEUTICAL INC , a remarkable value stock. NASDAQ:BMRN excels in fundamentals and maintains a very reasonable valuation. 
Via Chartmill
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX,... 
Via Benzinga
NASDAQ:BMRN is showing decent growth, but is still valued reasonably.
Don't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators
Alger launched its INVN ETF, with holdings including BioMarin, Teradata, and Bristol-Myers Squibb. 
Via Benzinga
Topics ETFs
10 Magnificent Stocks That Can Make You Richer in 2025
A new year brings with it new opportunities to grow your wealth on Wall Street. 
Via The Motley Fool
NASDAQ:BMRN stands out as a stock that provides good value for the fundamentals it showcases.
In a market where value is scarce, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Despite its growth, NASDAQ:BMRN remains within the realm of affordability. 
Via Chartmill
When you look at NASDAQ:BMRN, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
In a market where value is scarce, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
Can BioMarin Stock Live Up to Wall Street’s High Expectations?
BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon? 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS